Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 3/18/22 → 1/29/25 |
Funding
- UCB Biopharma SRL (Belgium): $129,585.00
ORAL UCB0599: A Double-blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Oral UCB0599 In Study Participants With Early Parkinson's Disease
- Slevin, John (PI)